Viventia Biotechnologies Inc. - Product Pipeline Review - 2012

Date: July 16, 2012
Pages: 33
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: VC6F1545844EN
Leaflet:

Download PDF Leaflet

  • Abstracts
  • Contents
Viventia Biotechnologies Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Viventia Biotechnologies Inc. - Product Pipeline Review - 2012” provides data on the Viventia Biotechnologies Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Viventia Biotechnologies Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Viventia Biotechnologies Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Viventia Biotechnologies Inc. - Brief Viventia Biotechnologies Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Viventia Biotechnologies Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Viventia Biotechnologies Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Viventia Biotechnologies Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Viventia Biotechnologies Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Viventia Biotechnologies Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Viventia Biotechnologies Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Viventia Biotechnologies Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Viventia Biotechnologies Inc. and identify potential opportunities in those areas.
Keywords

Current R&D Portfolio of Viventia Biotechnologies Inc.; Viventia Biotechnologies Inc. - Key Therapeutics; Viventia Biotechnologies Inc. - Pipeline Overview and Promising Molecules; Viventia Biotechnologies Inc. - News; Viventia Biotechnologies Inc. - Latest Updates; Viventia Biotechnologies Inc. - Pipeline; Viventia Biotechnologies Inc. - Discontinued/Dormant Projects
Viventia Biotechnologies Inc. Snapshot
Viventia Biotechnologies Inc. Overview
Key Information
Key Facts
Viventia Biotechnologies Inc. – Research and Development Overview
Key Therapeutic Areas
Viventia Biotechnologies Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Viventia Biotechnologies Inc. – Pipeline Products Glance
Viventia Biotechnologies Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Viventia Biotechnologies Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Viventia Biotechnologies Inc. – Drug Profiles
VB6-008
Product Description
Mechanism of Action
R&D Progress
VB6-011
Product Description
Mechanism of Action
R&D Progress
VB6-050
Product Description
Mechanism of Action
R&D Progress
VB6-845
Product Description
Mechanism of Action
R&D Progress
Vicinium
Product Description
Mechanism of Action
R&D Progress
Viventia Biotechnologies Inc. – Pipeline Analysis
Viventia Biotechnologies Inc. – Pipeline Products by Therapeutic Class
Viventia Biotechnologies Inc. – Pipeline Products By Target
Viventia Biotechnologies Inc. – Pipeline Products by Route of Administration
Viventia Biotechnologies Inc. - Dormant Projects
Viventia Biotechnologies Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
GPI-2A
Viventia Biotechnologies Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Viventia Biotechnologies Inc., Deals Summary
Viventia Biotechnologies Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Viventia Secured $23 Million In Venture Financing
Partnerships
EvoGenix Enters Into Research Agreement With Viventia
Licensing Agreements
Dowpharma Signs A License Agreement With Viventia Biotech
Viventia Biotech Enters Into A Collaboration With ESBATECH
Acquisition
Dan Group Acquires Viventia Biotech
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Viventia Biotechnologies Inc., Key Information
Viventia Biotechnologies Inc., Key Facts
Viventia Biotechnologies Inc. – Pipeline by Indication, 2012
Viventia Biotechnologies Inc. – Pipeline by Stage of Development, 2012
Viventia Biotechnologies Inc. – Monotherapy Products in Pipeline, 2012
Viventia Biotechnologies Inc. – Phase II, 2012
Viventia Biotechnologies Inc. – Phase I, 2012
Viventia Biotechnologies Inc. – Pre-Clinical, 2012
Viventia Biotechnologies Inc. – Pipeline By Therapeutic Class, 2012
Viventia Biotechnologies Inc. - Pipeline By Target, 2012
Viventia Biotechnologies Inc. – Pipeline By Route of Administration, 2012
Viventia Biotechnologies Inc. - Dormant Developmental Projects,2012
Viventia Biotechnologies Inc. - Discontinued Pipeline Products, 2012
Viventia Biotechnologies Inc., Other Locations
Viventia Biotechnologies Inc., Deals Summary
Viventia Secured $23 Million In Venture Financing
EvoGenix Enters Into Research Agreement With Viventia
Dowpharma Signs A License Agreement With Viventia Biotech
Viventia Biotech Enters Into A Collaboration With ESBATECH
Dan Group Acquires Viventia Biotech

LIST OF FIGURES

Viventia Biotechnologies Inc. – Pipeline by Indication, 2012
Viventia Biotechnologies Inc. – Pipeline by Stage of Development, 2012
Viventia Biotechnologies Inc. – Monotherapy Products in Pipeline, 2012
Viventia Biotechnologies Inc. – Pipeline By Route of Administration, 2012

Ask Your Question

Viventia Biotechnologies Inc. - Product Pipeline Review - 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: